WallStreetZenWallStreetZen

NASDAQ: PODD
Insulet Corp Stock

$180.07+9.28 (+5.43%)
Updated May 24, 2024
PODD Price
$180.07
Fair Value Price
-$73.01
Market Cap
$12.61B
52 Week Low
$125.82
52 Week High
$297.19
P/E
53.75x
P/B
15.95x
P/S
6.73x
PEG
5.24x
Dividend Yield
N/A
Revenue
$1.78B
Earnings
$234.00M
Gross Margin
68.9%
Operating Margin
15.45%
Profit Margin
13.1%
Debt to Equity
2.32
Operating Cash Flow
$233M
Beta
0.95
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

PODD Overview

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Zen Score

Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PODD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

PODD ($180.07) is overvalued by 346.64% relative to our estimate of its Fair Value price of -$73.01 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
PODD ($180.07) is not significantly undervalued (346.64%) relative to our estimate of its Fair Value price of -$73.01 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
PODD ($180.07) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PODD due diligence checks available for Premium users.

Be the first to know about important PODD news, forecast changes, insider trades & much more!

PODD News

Valuation

PODD fair value

Fair Value of PODD stock based on Discounted Cash Flow (DCF)
Price
$180.07
Fair Value
-$73.01
Undervalued by
346.64%
PODD ($180.07) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PODD ($180.07) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PODD ($180.07) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

PODD price to earnings (PE)

For valuing profitable companies with steady earnings
Company
53.75x
Industry
30.23x
Market
32.03x
PODD is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
PODD is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation

PODD price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
15.95x
Industry
3.95x
PODD is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

PODD price to earnings growth (PEG)

For valuing profitable companies with growth potential
PODD is poor value relative... subscribe to Premium to read more.
PEG Value Valuation

PODD's financial health

Profit margin

Revenue
$441.7M
Net Income
$51.5M
Profit Margin
11.7%
PODD's Earnings (EBIT) of $275.10M... subscribe to Premium to read more.
Interest Coverage Financials
PODD's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$2.6B
Liabilities
$1.8B
Debt to equity
2.32
PODD's short-term assets ($1.62B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PODD's short-term assets ($1.62B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PODD's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PODD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$87.6M
Investing
-$24.0M
Financing
-$14.1M
PODD's operating cash flow ($232.80M)... subscribe to Premium to read more.
Debt Coverage Financials

PODD vs Medical Device Stocks

TickerMarket Cap1d %P/EP/B
PODD$12.61B+5.43%53.75x15.95x
SWAV$12.55B+0.01%75.60x16.69x
BRKR$11.23B+0.72%28.09x7.93x
SNN$10.91B+0.89%41.18x2.09x
GMED$8.89B+0.66%111.56x2.27x

Insulet Stock FAQ

What is Insulet's quote symbol?

(NASDAQ: PODD) Insulet trades on the NASDAQ under the ticker symbol PODD. Insulet stock quotes can also be displayed as NASDAQ: PODD.

If you're new to stock investing, here's how to buy Insulet stock.

What is the 52 week high and low for Insulet (NASDAQ: PODD)?

(NASDAQ: PODD) Insulet's 52-week high was $297.19, and its 52-week low was $125.82. It is currently -39.41% from its 52-week high and 43.12% from its 52-week low.

How much is Insulet stock worth today?

(NASDAQ: PODD) Insulet currently has 70,039,511 outstanding shares. With Insulet stock trading at $180.07 per share, the total value of Insulet stock (market capitalization) is $12.61B.

Insulet stock was originally listed at a price of $15.96 in May 15, 2007. If you had invested in Insulet stock at $15.96, your return over the last 17 years would have been 1,028.26%, for an annualized return of 15.32% (not including any dividends or dividend reinvestments).

How much is Insulet's stock price per share?

(NASDAQ: PODD) Insulet stock price per share is $180.07 today (as of May 24, 2024).

What is Insulet's Market Cap?

(NASDAQ: PODD) Insulet's market cap is $12.61B, as of May 25, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Insulet's market cap is calculated by multiplying PODD's current stock price of $180.07 by PODD's total outstanding shares of 70,039,511.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.